Alivus Life Sciences

Highly Engaged Employees

Alivus Life Sciences Limited, formerly known as Glenmark Life Sciences Limited, is a publicly traded Indian pharmaceutical company headquartered in Mumbai, India, specializing in the development and manufacturing of select high-value, non-commoditized Active Pharmaceutical Ingredients in chronic therapeutic areas. Founded in 2001 as the API busines... s unit of Glenmark Pharmaceuticals, the company was spun off into an independent entity called Glenmark Life Sciences in 2019 and subsequently listed on the Bombay Stock Exchange and National Stock Exchange in 2021. In March 2024, Nirma Limited, a diversified conglomerate with interests in consumer products, cement, chemicals, and pharmaceuticals headquartered in Ahmedabad, acquired 75 percent of the issued and paid-up equity share capital of Glenmark Life Sciences from Glenmark Pharmaceuticals, becoming the new promoter of the company. The company officially rebranded from Glenmark Life Sciences to Alivus Life Sciences in January 2025, with the new identity representing vitality and growth and reflecting the company's evolving vision aimed at further strengthening its global presence and commitment to providing innovative solutions in the API and contract development and manufacturing organization space. Alivus Life Sciences operates four state-of-the-art manufacturing facilities located in Ankleshwar, Dahej, Mohol, and Kurkumbh in India, with a total installed capacity of 1,424 kiloliters, all of which are regularly inspected and approved by global regulators including the United States Food and Drug Administration, PMDA Japan, EDQM Europe, Health Canada, ANVISA Brazil, and regulatory authorities in the United Kingdom, European Union, South Korea, and other countries. The company has a diversified portfolio of 161 molecules and supplies its products to customers across India, Europe, North America, Latin America, Japan, and the rest of the world, with approximately 85 percent of revenue derived from regulated markets and 15 percent from emerging markets. Alivus ...Read More